30 January 2020 in PLOS ONE
Inflammation is a hallmark of cancer whose activity is modulated within the tumor microenvironment by low tumoral pH. Recent evidence in the literature has suggested a link between low serum bicarbonate, low tumoral pH and cancer related inflammation. There is however little clinical evidence in human patients regarding the prognostic role of serum bicarbonate. Therefore, the primary aim of this study was to investigate the short and long-term prognostic utility of serum bicarbonate in colorectal cancer (CRC) patients undergoing resection of their primary tumor. The study also aimed to investigate the association of serum bicarbonate with known markers of systemic inflammation. A total of 3281 consecutive patients who underwent surgical resection of their primary CRC from January 1998 to December 2012. Of these, 2223 stage I-IV patients had available data for analysis. The association of serum bicarbonate with overall survival was assessed using univariate and multivariate cox regression analyses. The association of bicarbonate with other clinicopathological variables was assessed by chi squared and Fisher’s exact tests. Serum bicarbonate was associated with peri-operative mortality in multivariate analysis (p<0.001). Age (p = 0.004), grade (p = 0.043), creatinine (p = 0.036) and sodium (p = 0.036) were also markers associated with peri-operative mortality. For long term survival at 5 years, bicarbonate was significantly associated with overall survival in univariate analysis (p<0.001) but was not significant in multivariate analysis (p = 0.075). In exploratory analysis, serum bicarbonate was found to be significantly associated with the lymphocyte-to-monocyte ratio (p<0.001) and neutrophil-to-lymphocyte ratio (p<0.001). In peri-operative colorectal cancer patients, serum bicarbonate was associated with 30-day survival but not 5-year survival.
19 August 2025 in Journal of Medical Imaging and Radiation Oncology
Introduction: Long term survival for adenoid cystic carcinoma (ACC) arising from the head and neck declines for many decades after initial treatment due to late disease relapse. Follow up and surveillance imaging practices vary due to limited evidence as well as a lack of international guidelines (until 2021).Methods: A retrospective cohort study was conducted for patients treated curatively for ACC between 2007 and 2024 at a single institution. Clinicopathologic information, treatment details, patterns of follow‐up (including radiologic investigations) and oncological outcomes are reported.Results: 51 patients comprised the study cohort. Median age was 50 years; 96% of patients underwent surgery and adjuvant radiation therapy. Median follow‐up was 7.65 years. 5‐year overall survival (OS) and disease‐free survival (DFS) were 88% and 73% respectively. 18% and 61% of patients underwent surveillance imaging within 3‐ and 12‐months of treatment completion respectively. 80% of first recurrences were detected on surveillance imaging. Half the episodes of first disease recurrence occurred within 5 years of initial treatment, a further 25% within 10 years and the remaining 25% occurred > 10 years post treatment.Conclusion: This cohort of patients curatively treated for ACC at a single institution highlights the propensity for late distant relapse as well as heterogeneity of surveillance imaging. A local institutional protocol is proposed based upon the 2021 ASCO guidelines to standardise clinical and radiologic follow‐up for this group.
17 July 2026 in Radiotherapy and Oncology
Volumetric modulated arc therapy (VMAT) in breast radiotherapy has seen limited uptake in routine care. Barriers to adoption include concerns regarding toxicity, dosimetry and low dose wash. There is a lack of modern data to address these concerns. Therefore, the aim of this study is to report on real-world outcomes from a single-class solution implementation of VMAT planned with knowledge-based planning (KBP). A retrospective review of all breast cancer patients undergoing definitive radiotherapy at Royal North Shore Hospital (Sydney, Australia) from June 2020 to June 2023 inclusive was undertaken. All patients were treated with a VMAT technique and planned with KBP. Prospectively collected dosimetry and toxicity data was collated. We identified 484 patients satisfying the inclusion criteria. Doses to constraints easily met international guidelines. For breast/chest-wall alone patients (n = 349), the median average heart dose was <2 Gy for standard fractionation (SF), <1.05 Gy for hypofractionated (HF) and <0.7 Gy for ultrahypofractionated (UHF) patients. The median average ipsilateral lung dose was <7.7 Gy for SF patients, <5.3 Gy for HF patients and <3.6 Gy for UHF patients. Nearly all patients (99%) achieved at least D95% ≥ 95% of the prescribed dose (TD) to the CTV primary. For acute toxicity, there were no clinician-reported high grade (Grade ≥ 3) toxicities and no pneumonitis recorded. This study demonstrates the technical feasibility, excellent dosimetry, and low clinician-reported acute toxicity of a standardised KBP-VMAT approach within a large, real-world cohort. Our approach easily met constraints set in recent international guidelines and randomised controlled trial protocols. While limited by its retrospective, single-arm nature and lack of long-term toxicity outcomes, this study adds to a growing body of literature on the use and outcomes of modern VMAT in breast radiotherapy.
8 October 2026 in Clinical Lung Cancer
16 June 2025 in Journal of Medical Imaging and Radiation Oncology
Introduction: The role of stereotactic body radiotherapy (SBRT) remains unclear in the setting of pancreatic ductal adenocarcinoma (PDAC). This study aims to investigate the safety, feasibility and benefits of SBRT for PDAC in a clinical trial setting.Methods: SPAN‐C was a single centre, single‐arm, phase II clinical trial. Patients with locally advanced, borderline resectable, and metastatic PDAC suitable for high dose radiation were enrolled. Fiducial marker placement was mandated. Following induction chemotherapy, patients were treated with 40‐45Gy in 5 fractions of external beam radiotherapy. Freedom from local failure at 12 months was the primary endpoint. Secondary endpoints included disease recurrence endpoints, acute and late toxicity, surgical outcomes, and palliative endpoints.Results: Thirty patients were enrolled. Median follow up of alive patients was 5 years (min 31 months). Twenty‐six completed treatment as per protocol. Nine patients (34.6%) underwent a resection, 5 of whom had a R0 resection and 2 had a complete pathologic response. The 12‐month freedom from local failure was 100% for the resected subgroup and 76.5% for the unresected subgroup. Seven patients (26.9%) had local recurrences, with 5 of these in the unresected group (29.4%). Median OS was 37.9 months for the resected subgroup and 10.7 months for the unresected subgroup. Three patients had grade 3 acute toxicity, and no patients had late high‐grade toxicity.Conclusions: SBRT was safe and feasible with high rates of local control at 12 months and low rates of toxicity. It appears a valid alternative to chemo‐irradiation in both the pre‐operative and inoperable setting.Trial Registration: ClinicalTrials.gov identifier: NCT03505229